• Analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price
• Data from pre-clinical trial indicate that BiondVax’s NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, further enhancing its value proposition
• BVXV reiterated further NanoAb development beginning with NanoAbs targeting immune system cytokines such as IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
• BiondVax aims to optimize the use of assets and generate additional revenues by offering its drug development services and cGMP manufacturing capabilities to others

BiondVax Pharmaceuticals (NASDAQ: BVXV), an innovative biotechnology company developing unique NanoAb immunotherapeutic products for the treatment of infectious disease and large market autoimmune disorders, recently published the financial results for the three months ended March 31, 2023 – Q1 2023 – and provided a business update (https://ibn.fm/GBZmz).

The Q1 2023 results were in line with analysts’ expectations. R&D expenses increased about $800k from Q1 2022 which BiondVax attributed to the initiation and ramp-up of R&D activities for its innovative nanosized VHH antibody (“NanoAb”) platform. In particular, the company finalized a preclinical…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.